Physician profile
David Hoffman
NPI 1538165675
$1,166.33
in general payments reported to CMS, 2019-2025
13 companies · $199 in 2025
The $199 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.22 · 2020: $173 · 2021: $111 · 2022: $317 · 2023: $60.82 · 2024: $289 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $250.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $238.17 | 2023-2025 | |
| Genzyme Corporation | $221.30 | 2024-2025 | |
| Coherus Oncology, INC. | $123.83 | 2020-2021 | |
| Janssen Biotech, INC. | $91.91 | 2020-2024 | Rybrevant |
| Pfizer INC. | $64.28 | 2019-2022 | |
| Tersera Therapeutics LLC | $40.38 | 2021 | |
| Lilly USA, LLC | $34.66 | 2025 | Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $32.75 | 2022 | |
| Csl Behring | $21.88 | 2021 | |
| Octapharma USA, INC. | $19.09 | 2024 | Octagam Immune Globulin (Human) |
| Beigene USA, INC. | $16.16 | 2023 | Brukinsa |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.